Tang Rong, Liu Yu-Qian, Zhong Hai-Lian, Wu Fang, Gao Shi-Xiong, Liu Wei, Lu Wen-Sheng, Wang Ying-Bin
Department of Anesthesiology, Lanzhou University Second Hospital, Lanzhou, China.
Front Pharmacol. 2022 Sep 29;13:952441. doi: 10.3389/fphar.2022.952441. eCollection 2022.
Dexmedetomidine is considered an adjunct to local anaesthesia (LA) to prolong peripheral nerve block time. However, the results from a previous meta-analysis were not sufficient to support its use in paravertebral block (PVB). Therefore, we performed an updated meta-analysis to evaluate the efficacy of dexmedetomidine combined with LA in PVB. We performed an electronic database search from the date of establishment to April 2022. Randomized controlled trials (RCTs) investigating the combination of dexmedetomidine and LA compared with LA alone for PVB in adult patients were included. Postoperative pain scores, analgesic consumption, and adverse reactions were analyzed. We identified 12 trials (701 patients) and found that the application of dexmedetomidine as a PVB adjunct reduced the postoperative pain severity of patients 12 and 24 h after surgery compared to a control group. Expressed as mean difference (MD) (95% CI), the results were -1.03 (-1.18, -0.88) ( < 0.00001, I = 79%) for 12 h and -1.08 (-1.24, -0.92) ( < 0.00001, I = 72%) for 24 h. Dexmedetomidine prolonged the duration of analgesia by at least 173.27 min (115.61, 230.93) ( < 0.00001, I = 81%) and reduced postoperative oral morphine consumption by 18.01 mg (-22.10, 13.92) ( < 0.00001, I = 19%). We also found no statistically significant differences in hemodynamic complications between the two groups. According to the GRADE system, we found that the level of evidence for postoperative pain scores at 12 and 24 h was rated as moderate. Our study shows that dexmedetomidine as an adjunct to LA improves the postoperative pain severity of patients after surgery and prolongs the duration of analgesia in PVB without increasing the incidence of adverse effects.
右美托咪定被认为是局部麻醉(LA)的辅助药物,用于延长周围神经阻滞时间。然而,先前一项荟萃分析的结果不足以支持其在椎旁阻滞(PVB)中的应用。因此,我们进行了一项更新的荟萃分析,以评估右美托咪定联合LA在PVB中的疗效。我们从数据库建立之日至2022年4月进行了电子数据库检索。纳入了调查右美托咪定与LA联合应用与单独使用LA用于成年患者PVB的随机对照试验(RCT)。分析了术后疼痛评分、镇痛药物消耗量和不良反应。我们确定了12项试验(701例患者),发现与对照组相比,应用右美托咪定作为PVB辅助药物可降低患者术后12小时和24小时的疼痛严重程度。以平均差(MD)(95%CI)表示,12小时时的结果为-1.03(-1.18,-0.88)(P<0.00001,I² = 79%),24小时时为-1.08(-1.24,-0.92)(P<0.00001,I² = 72%)。右美托咪定将镇痛持续时间延长了至少173.27分钟(115.61,230.93)(P<0.00001,I² = 81%),并使术后口服吗啡消耗量减少了18.01毫克(-22.10,13.92)(P<0.